Juno Therapeutics (JUNO) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to Juno Therapeutics (JUNO) Tops Q1 EPS by 4c
May 11, 2015 4:06 PM EDT
Conference call to be held on Monday, May 11, 2015 at 5:00 p.m. Eastern Time
-Â Positive momentum on clinical trials and research continuesÂ
-Â Multiple strategic transactions further strengthen technology platform and capabilitiesÂ
-Â Strong quarter-end cash position of $447.6 millionÂ
-Â Affirmed 2015 cash burn guidance of $125 million to $150 million, excluding cash inflows or outflows from business development activities and now-settled litigation
SEATTLE, May 11, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to... More
May 11, 2015 4:02 PM EDT
Transaction Provides Transformative Cell Selection and Activation Capabilities, Advanced Manufacturing Automation, Improved Supply Chain, and Lower Expected Cost of Goods
Initial Payment of 52.5 Million in Cash (Approximately $59 Million) and 486,279 Shares of Juno Stock
SEATTLE, May 11, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced today that it has acquired Stage Cell Therapeutics GmbH ("Stage"), a privately held biotechnology company based in Munich and Göttingen, Germany. The transaction furthers Juno's strategy of being a world leader in... More
